Floatz logo

SUFENTANYL

Carcinoma, Non-Small-Cell Lung

Peking University First HospitalSmall moleculePhase 4 / ApprovedDormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
65/ 100

Competitive context

114 Active assets in the Carcinoma, Non-Small-Cell Lung cohort.

Asset / SponsorPhaseRating
Lazertinib
Janssen Research & Development, LLC
Phase 3BB
DEXAMETHASONE
Rigshospitalet, Denmark
Phase 4BB
Vibostolimab
Merck Sharp & Dohme LLC
Phase 3BB
Lorlatinib
Chugai Pharmaceutical
Phase 4BB
IMMUNOGLOBULIN G4, ANTI-(HUMAN HEPATOCYTE GROWTH FACTOR RECEPTOR) (HUMAN-MUS MUSCULUS MONOCLONAL LY2875358 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL LY2875358 .KAPPA.-CHAIN, DIMER
Eli Lilly and Company
Phase 2BB

View all 50 →

Same molecule, other indications

SUFENTANYL is also rated in:

chronic pain syndromeDormant
BB
Indicative ·
69 / 100
View asset →
AnalgesicsDormant
BB
Indicative ·
68 / 100
View asset →
Post Operative PainDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →